Thank you
This live web event has ended. Thank you for attending.
Description
![](https://s3.amazonaws.com//bluesky_portal_prod/uploads/redactor_images/1587159470.5873373_Adaptive-CT_logo.jpg)
Standardizing minimal residual
disease (MRD) assessment in
lymphoid malignancies using NGS
Why should you register now for this webinar?
- Understand how advances in NGS are enabling a more sensitive, specific, and standardized approach to MRD assessment in lymphoid malignancies
- Brought to you by: CAP TODAY
- Moderated by Bob McGonnagle, Publisher, CAP TODAY
- Presenter: Mohammad Hussaini, MD
What will this webinar empower you to do?
- Compare and contrast NGS with other methodologies to measure MRD
- Review single-institution experience across disease spectrum including multiple myeloma, acute lymphoblastic leukemia, mantle cell lymphoma, and chronic lymphocytic leukemia
- Understand how NGS MRD can be used in the clinical management of lymphoid malignancies
- Ask questions of our distinguished presenter
CAP TODAY does not endorse any of the products or services named within.
The webinar is made possible by a special educational grant from Adaptive Biotechnologies.